LATEST TRIALS

  • Lung Cancer, Melanoma
    Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
  • Melanoma
    A Randomized Phase II, Open-label, Active-controlled, Multicenter Study Investigating the Efficacy and Safety of UV1 Vaccination in Combination with Nivolumab and Ipilimumab as First-line Treatment of Patients with Unresectable or Metastatic Melanoma
  • Lung Cancer
    Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients

NORDIC COOPERATION

Norway Norway Sweden Finland Finland Finland Aarhus Herlev Copenhagen Copenhagen Lund